Ardan Equity and GI Partners take co-control of Clinical Ink
Ardan Equity and GI Partners have each invested new equity in clinical trial technology company Clinical Ink under a co-control partnership.
Private equity firms Ardan Equity and GI Partners have each invested new equity in Clinical Ink under a co-control partnership. Financial terms of the transaction were not disclosed.
Ardan invested through Ardan Equity Fund I, while GI Partners invested through GI Partners Fund VI. Existing investors, including GI Partners Fund V, realized a full exit of their investments.
GI Partners first invested in Clinical Ink in 2020. According to Noah Lewis, managing partner at Ardan, the transaction represents the first investment from Ardan Equity Fund I and Ardan’s eighth platform investment since 2020.
Headquartered in Winston-Salem, Clinical Ink provides electronic clinical outcome assessments (eCOA), connected devices, and other eClinical technologies. Led by CEO Jonathan Goldman, the company helps pharmaceutical companies and contract research organizations capture complex clinical trial data, maintaining additional offices in Iowa, Pennsylvania, and Copenhagen.
Under GI Partners' ownership, Clinical Ink expanded its global footprint and platform, grew revenue, and moved into more therapeutic areas. The company has also expanded into disease management with its Kaitality app.